Eye dis­ease spe­cial­ists ven­ture in­to M&A with a buy­out deal worth up to $126M

Kala Phar­ma­ceu­ti­cals con­tin­ued their tran­si­tion to a com­mer­cial-stage biotech late last year with its sec­ond OK af­ter a long slog through the clin­ic. Now the biotech’s ex­ecs are turn­ing to M&A to grow the com­pa­ny.

The Wa­ter­town, MA eye-fo­cused biotech an­nounced its ac­qui­si­tion of pri­vate oc­u­lar biotech Com­ban­gio this morn­ing. Com­ban­gio, a Cal­i­for­nia biotech which has re­mained un­der the radar, was in the mid­dle of de­vel­op­ing a se­cre­tome ther­a­py — and had re­cent­ly fin­ished a Phase Ib tri­al, en­rolling 8 pa­tients with per­sis­tent corneal ep­ithe­lial de­fect, or PCED with pos­i­tive re­sults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER